Algeria has opened talks with Hungary on expanding bilateral cooperation in pharmaceutical manufacturing and clinical research, in the latest sign of the North African country's continuing push to attract foreign technical expertise into one of its more strategically prioritised industrial sectors.

Rocket Pharmaceuticals, the US gene therapy specialist, has bought itself an additional two years of operational runway through the $180mn sale of a regulatory voucher, easing pressure on a balance sheet that had been narrowing as the New Jersey-based group navigated a difficult phase of pipeline development and corporate restructuring.

aTyr Pharma shares declined sharply after the company announced plans for a new Phase 3 study of efzofitimod in pulmonary sarcoidosis following discussions with the U.S. Food and Drug Administration.

Brano Therapeutics raised $6.8 million in seed financing to support the development of new therapies targeting heart failure, including Heart Failure with preserved Ejection Fraction (HFpEF), an area where treatment options remain limited.

Zealand Pharma shares climbed after the company reported positive clinical progress across its obesity pipeline and strengthened its financial outlook with expected milestone payments from partner Roche.

Germany proposed sweeping healthcare cost-cutting reforms aimed at reducing a projected €40 billion deficit in the country’s public health insurance system, raising concerns across the pharmaceutical and healthcare sectors.

 The chief executive of Acadia Pharmaceuticals has warned that President Donald Trump's "most favoured nation" pricing policy risks undermining the international research collaborations that have underpinned drug discovery for decades, in the latest sign of mounting industry concern over the regulatory and commercial direction of US pharmaceutical policy.

Neimeth International Pharmaceuticals, one of Nigeria's longest-established drugmakers, posted strong revenue growth in the first quarter of 2026, continuing a turnaround that has lifted the Lagos-listed group out of three years of losses — even as escalating finance costs and an entrenched debt load underscore how challenging the operating environment remains for the country's pharmaceutical industry.

Kazakhstan has approved an investment agreement underpinning a 42.5bn tenge (around $80mn) pharmaceutical production complex in the central region of Karaganda, in the latest step of a state-driven campaign to reduce the country's reliance on imported medicines and build a domestic manufacturing base in higher-value therapeutic categories.

Marty Makary has resigned as commissioner of the US Food and Drug Administration after months of internal turmoil, with White House staff having signed off on a plan to replace him last week.

Takeda Pharmaceutical (TAK) plans to eliminate around 4,500 jobs in fiscal year 2026 as part of a restructuring programme aimed at centralising corporate functions and reducing costs, the Japanese drugmaker said on Wednesday.

Rigel Pharmaceuticals has agreed to acquire exclusive global rights to Veppanu, the first FDA-approved therapy in a new class of cancer drugs that destroys disease-causing proteins rather than blocking them, paying $85mn upfront to Arvinas and Pfizer in a deal that materially repositions the South San Francisco-based group as a specialist commercial player in protein degradation oncology.

Milestone Pharmaceuticals, the dual-listed Canadian-US cardiovascular biotech, reported early commercial momentum for its newly launched nasal-spray heart rhythm therapy and confirmed the start of a late-stage trial in a second, larger indication, as it heads into the most operationally intensive phase in its corporate history.

Mira Pharmaceuticals, a small US clinical-stage biotech, has published peer-reviewed preclinical data for its experimental oral drug candidate SKNY-1, a compound being developed simultaneously as a treatment for obesity and nicotine addiction — a dual ambition that reflects the growing biological convergence between metabolic and addiction medicine.

EU member states have agreed to stockpile essential medicines and subsidise domestic production of key drugs in an effort to end persistent shortages and reduce dependence on imports from China and India.

Eli Lilly (LLY) has paused an obesity awareness campaign in India after the country's drugs regulator warned the company it may be breaching rules against advertising prescription medicines to consumers, even indirectly.

Polpharma, Poland's largest pharmaceutical group, has agreed to launch a voluntary public tender offer for Romanian drugmaker Biofarm at a valuation of approximately €270mn, marking one of the most significant cross-border consolidation moves in the central and eastern European pharmaceutical sector in recent years.

Analysts have cut their earnings forecasts for Fine Foods & Pharmaceuticals N.T.M., the Italian contract development and manufacturing group, after a first-quarter result that came in broadly in line with expectations but failed to prevent a sharp pullback in the share price.

GSK has struck an exclusive partnership with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of bepirovirsen, its closely watched experimental treatment for chronic hepatitis B, in mainland China — the largest single market for the disease and one of the most strategically significant geographies for what would be a first-in-class functional cure.

A New Jersey appeals court has revived whistleblower claims brought by a former compliance attorney at Novartis, reopening a case centred on alleged retaliation tied to internal compliance concerns.

The appellate court ruled that Cynthia Ham plausibly alleged a continuing pattern of retaliation under New Jersey’s Conscientious Employee Protection Act (CEPA), reversing an earlier decision that dismissed several claims as time-barred.